Tekmira Pharmaceuticals this week unveiled new preclinical data from its Ebola and Marburg virus programs, showing that its siRNA-based therapies were effective in non-human primates even when treatment was delayed by as much as 48 hours after infection.
Tekmira Pharmaceuticals this week said that the underwriters of its recent public stock offering of 3.75 million shares have exercised their over-allotment option to buy an additional 562,000 shares at $8 apiece.
RNAi drugs startup Arcturus Therapeutics this week announced that it has raised $5 million in a Series A round of financing, which comes just months after the company pulled in $1.5 million in seed money.
Tekmira Pharmaceuticals said this week that it has priced a public offering of 3.75 million shares of its common stock at $8 a share, for gross proceeds of $30 million.
Tekmira stock closed at $8.82 on Wednesday.
Less than a month after publishing data showing that siRNAs formulated in its lipid nanoparticles could provide 100 percent post-exposure protection against Marburg virus infection in guinea pigs, Tekmira Pharmaceuticals has announced similar findings in non-human primates.